- Home
- BATL vs CLDI Comparison
BATL vs CLDI Comparison
Compare BATL & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- CLDI
- Stock Information
- Founded
- BATL 1987
- CLDI 2014
- Country
- BATL United States
- CLDI United States
- Employees
- BATL N/A
- CLDI N/A
- Industry
- BATL Oil & Gas Production
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BATL Energy
- CLDI Health Care
- Exchange
- BATL Nasdaq
- CLDI Nasdaq
- Market Cap
- BATL 19.3M
- CLDI 20.2M
- IPO Year
- BATL N/A
- CLDI N/A
- Fundamental
- Price
- BATL $1.07
- CLDI $1.57
- Analyst Decision
- BATL
- CLDI
- Analyst Count
- BATL 0
- CLDI 0
- Target Price
- BATL N/A
- CLDI N/A
- AVG Volume (30 Days)
- BATL 387.2K
- CLDI 476.7K
- Earning Date
- BATL 08-14-2025
- CLDI 08-08-2025
- Dividend Yield
- BATL N/A
- CLDI N/A
- EPS Growth
- BATL N/A
- CLDI N/A
- EPS
- BATL N/A
- CLDI N/A
- Revenue
- BATL $185,206,000.00
- CLDI N/A
- Revenue This Year
- BATL N/A
- CLDI N/A
- Revenue Next Year
- BATL N/A
- CLDI N/A
- P/E Ratio
- BATL N/A
- CLDI N/A
- Revenue Growth
- BATL N/A
- CLDI N/A
- 52 Week Low
- BATL $1.02
- CLDI $1.51
- 52 Week High
- BATL $6.89
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- BATL 35.35
- CLDI 29.64
- Support Level
- BATL $1.02
- CLDI $1.51
- Resistance Level
- BATL $1.21
- CLDI $1.73
- Average True Range (ATR)
- BATL 0.09
- CLDI 0.30
- MACD
- BATL 0.00
- CLDI -0.03
- Stochastic Oscillator
- BATL 18.52
- CLDI 1.66
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.